Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 11 April

Grady Wulff
April 11, 2024

Morning Bell 10 April

Grady Wulff
April 10, 2024

Morning Bell 9 April

Sam Kanaan
April 9, 2024

Morning Bell 8 April

Grady Wulff
April 8, 2024

Morning Bell 5 April

Sam Kanaan
April 5, 2024

Morning Bell 4 April

Sophia Mavridis
April 4, 2024

Morning Bell 3 April

Grady Wulff
April 3, 2024

Morning Bell 2 April

Sam Kanaan
April 2, 2024

Morning Bell 28 March

Sam Kanaan
March 28, 2024

Morning Bell 27 March

Grady Wulff
March 27, 2024

Morning Bell 26 March

Grady Wulff
March 26, 2024